期刊文献+

阿托伐他汀的应用与研究概况 被引量:4

在线阅读 下载PDF
导出
摘要 阿托伐他汀是羟甲基戊二酸单酰辅酶A(HMG-CoA)还原酶抑制剂,此药通过竞争性抑制内源性胆固醇合成限速HMG-CoA还原酶,阻断细胞内甲羟戊酸代谢途径,使细胞内胆固醇合成减少[1-2]。此药除具有降低血清总胆固醇(TC)、升高高密度脂蛋白胆固醇(HDL-ch)作用外,还发现它具有抗炎、抗氧化、改善血管内皮功能、抑制血小板激活、降低血液黏度、
出处 《中国医院用药评价与分析》 2013年第6期570-572,共3页 Evaluation and Analysis of Drug-use in Hospitals of China
  • 相关文献

参考文献22

二级参考文献161

共引文献152

同被引文献51

  • 1颜文飞,庞明杰.阿托伐他汀治疗老年高脂血症的临床疗效及安全性[J].昆明医科大学学报,2013,34(7):59-61. 被引量:4
  • 2李友元,邓洪波,向大雄,陈珑珑.黄精多糖的降血脂及抗动脉粥样硬化作用[J].中国动脉硬化杂志,2005,13(4):429-431. 被引量:77
  • 3张萍,刘丹,李友元.黄精多糖对动脉粥样硬化家兔血清IL-6及CRP的影响[J].医学临床研究,2006,23(7):1100-1101. 被引量:27
  • 4Shin J,Pauly DF,Pacanowski MA. Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin[J].PHARMACOTHERAPY,2011,(10):942-950.
  • 5Furman A,Meier JL,Malmstrom RA. Comparative efficacy of ezetimibe/simvastatin,rosuvastatin,and atorvastatin in uncontrolled hyperlipidemia patients[J].AMERICAN JOURNAL OF MANAGED CARE,2011,(08):538-544.
  • 6Yu XL,Zhang HJ,Ren SD. Effects of loading dose of atorvastatin before percutaneous coronary intervention on periprocedural myocardial injury[J].Coronary Artery Disease,2011,(01):87-91.
  • 7Robinson JG,Ballantyne CM,Grundy SM. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study)[J].American Journal of Cardiology,2009,(12):1694-1702.
  • 8O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary:a report of the American College of Cardiology Foundation/" American HeartAssociation Task Force on Practice Guidelines[ J ]. Circulation ,2013,127 (4) :529 - 555.
  • 9Yun KH,Shin IS,Shin SN,et al. Effect of previous statin therapy in patients with acute coronary syndrome and percutaneous coronary in- tervention[ J]. Korean Circ J,2011,41 (8) :458 -463.
  • 10Sardella G,Conti G, Donahue M, et al. Rosuvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of myocar- dial periprocedural necrosis : the ROMA trial [ J ]. Catheter Cardio- vasc Interv,2013,81 ( 1 ) :E36 - E43.

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部